This study examines whether labour outcomes of HIV-infected workers treated with antiretrovirals are associated with the stage of the disease when commencing therapy. We use data on employment separation and absenteeism from the workplace health programme of South Africa's largest coal mining company 
INTRODUCTION
In 2016, 25.6 million people, primarily of working age, were living with HIV infection in Africa and now accounts for two thirds of all new infections globally (World Health Organization, 2017) . In South Africa, where our study took place, the prevalence of HIV among those aged 15-49 is currently 20.6% (SABSSM, 2018) . Among the most important economic consequences of the disease is the impact of HIV-related sickness and deaths on the workforce (World Health Organization, 2008) . Although studies have shown that treatment with antiretroviral therapy (ART) can eliminate much of the adverse impact, there is currently very little known on the degree to which labour outcomes depend on how sick workers are when they commence therapy (Thirumurthy et al., 2013; Tirivayi & Koethe, 2016) . Although many companies and the South African government have adopted universal test-and-treat policies, aiming to initiate all HIV-infected people as early as possible, most HIV patients still start treatment late in the disease course when the symptom burden is higher.
In this paper, we investigate whether the timing of ART is associated with labour outcomes among workers in South Africa's largest coal mining company. Our study is the first to longitudinally examine the effect of disease stage at treatment start on employment separation and on the more responsive labour outcome of absenteeism. These labour outcome measures are important. Loss of work can have severe economic and social consequences for the worker (Hoffman, 1997) . From the perspective of the firm, a lost worker implies the transaction costs of hiring and training a new worker and absenteeism reduces the productivity of the existing workforce (Rosen et al., 2004) . Our study is also the first to examine the differences in absenteeism by timing of ART initiation in the period before treatment has started. This first evidence is important in order to have a complete picture of the economic losses due to late ART initiation. The nonexperimental design of our study precludes strong causal conclusions because we cannot rule out endogenous selection into disease stage at ART initiation. However, we condition on a number of potentially important sources of endogenous selection allowing causal inferences that are stronger than those based on unconditional associations.
A person infected with HIV may initially experience mild flu-like symptoms as the virus replicates progressing to a prolonged latent phase where HIV symptoms gradually appear and infection-fighting CD4 + T cells of the immune system steadily decline with time. Employment and productivity can be negatively affected as symptoms of physical and cognitive impairment often appear episodically and opportunistic infections and co-morbidities develop such as tuberculosis, hepatitis C, arthritis, or mental health problems (Groß et al., 2016; O'Brien et al., 2014) , and Beard, Feeley, and Rosen (2009) highlight higher levels of absenteeism among infected co-workers. Worthington, O'brien, Zack, Mckee, and Oliver (2012) report that people living with HIV/AIDS prefer to work but often struggle to maintain paid employment due to the sequelae of HIV, time demands, and side effects of some ART treatments as well as stigmatization in the workplace. Separation is therefore not only a negative outcome for the employer but also generally for the employee.
Progression of HIV disease can be halted and reversed through the use of ART, and this treatment has been shown to lead to increased productivity (Larson et al., 2008) , employment recovery (Bor, Tanser, Newell, & Bärnighausen, 2012) , and a reduction in absenteeism (Habyarimana, Mbakile, & Pop-Eleches, 2010 ) to predisease levels. Initially, treatment guidelines in most countries in Africa recommended ART treatment when the patient's CD4 cell count had fallen below 200 cells/ l, but countries have followed the World Health Organization (WHO) in revising its recommendations on the timing of ART initiation to higher CD4 counts. The rationale for these changes in recommendations is the strong evidence that earlier initiation reduces morbidity, mortality, and HIV transmission (Cohen et al., 2011; Insight Start Study Group, 2015) .
Disease stage at ART initiation can plausibly affect labour market outcomes through a number of mechanisms. First, patients who initiate ART late will take longer to recover their immunity and physical strength than patients who initiate ART earlier, and will thus suffer higher rates of absenteeism and employment separation. Second, even in the long run, immunity and physical strength may not return to normal levels in some of the patients who initiate ART late leading to higher rates of HIV-related diseases and poorer work performance. Third, it is also possible that patients who initiate ART late will face stigma and workplace discrimination because they have entered disease stages associated with physical manifestations clearly visible to others. However, to date, only one longitudinal study has examined how labour outcomes vary by the stage of the disease at ART initiation, finding that differences in the likelihood of working between those initiated on ART at CD4 < 200 and CD4 > 200 disappear within 1 year (Venkataramani et al., 2014) .
DATA AND METHODS

Data
Anonymised data from the workplace health programme of a South African coal mining company were collected over the period of January 2009 to March 2017 for all employees. At this time, this company was the largest coal producer in South Africa, owning and operating eight mines.
When the programme began, WHO guidance was that patients with HIV should commence ART if their CD4 count dropped below 200 cells/ l. WHO raised the threshold for ART treatment of HIV-infected patients from CD4 < 350 in 2010 to CD4 < 500 in 2013, and finally to all HIV patients at any CD4 count in 2015 (Maina et al., 2015) . However, medical officers for the health programme in our study did not closely adhere to these guidelines. The Chief Medical Officer's guidance over this period was that ART should be initiated when a patient with HIV was fully counselled; understood the diagnosis and treatment options; and was willing to voluntarily consent and commit to lifelong treatment. In practice, both patients and medical practitioners would have been aware of changing guidelines which would have influenced their joint decision on when to commence treatment.
All workers with HIV were treated at a company health service hospital, outpatients department, except those at two outlying sites where they attended ambulatory health centres. Access to treatment should not have been an issue for any of the employees at Anglo American Coal. All health services including ART treatment were provided free of charge to employees. Transport to and from the hospital or health centre was arranged by the mines and was also free. Notes. All workers employed between Jan2009 and Mar2017. Initial CD4 count given for all those initiating ART between Jan2009 and Mar2017. Absenteeism given over duration of ART. All other variables given at ART initiation.
Our data includes HIV status, the date of ART initiation as well as some demographics (age, marital status, and gender). A number of human resources variables also included in this data set, record the dates of engagement and termination of employment, if applicable, as well as occupation and work site. This data set was then merged with the data extracted from a separate system, recording dates of each day absent through sickness and linked to our data set using a unique employee identification number. Across 12,035 workers, absenteeism was typically 0.7 days per month and tenure was 9.81 years; although 16% of the workers were HIV positive, 81% were HIV negative, and the HIV status for the remaining 2% was unknown (Table 1) .
From January 2009 to March 2017, 885 workers commenced ART and 775 of these had a recorded CD4 test within 1 month of ART initiation. We categorize these 775 workers according to whether their initial CD4 cell count was below 200 cells/ l, 200 to 349 cells/ l, or 350 cells/ l and over. These categories were chosen to reflect the various ART initiation thresholds recommended by WHO or prevailing in South Africa (Maina et al., 2015; RSA Health, 2010; , and used in comparable studies in Uganda (Thirumurthy et al., 2013; Venkataramani et al., 2014) . A separate category of CD4 ≥ 500 was too small to support robust analysis (63 workers). Descriptive statistics for these three categories are compared in Table 1 . We see that absenteeism and tuberculosis (TB) prevalence are highest among those initiating at CD4 < 200, and that this category contains the lowest proportion of females. Of the category initiating at CD4 ≥ 350, a relatively high proportion initiated ART following the 2015 revision of WHO guidelines recommending ART for everyone living with HIV (19%) but also a significant percentage initiated ART before 2010 when WHO guidelines recommended therapy at CD4 < 200 (15%).
Statistical analysis
We first consider the variation in employment separation of those workers on ART within the company by initial CD4 count. The dependent variable in our model is the hazard rate or conditional probability that the worker will terminate her employment in a particular time period given that she was still working up until then. More formally, the hazard rate can be considered as the probability
where f(t) is the number of separations between t and t + 1, and N(t) is the number employed at the time, t. The proportion of workers remaining in the workforce until time, t, or "survival rate" provides another way of describing variations in employment separation and is given by
We use the Cox proportional hazards model to explain how the hazard of separation for a worker on ART varies by CD4 count (Cox, 1992) . In this model, the hazard rate is
where h 0 (t) is the baseline hazard and the vector x includes the CD4 count at ART initiation and a number of control variables. The effect of a unit change in x i ∈ x is expressed as a hazard ratio, e i , and this is assumed to be constant across time. If i is time-varying then (3) can be modified by the inclusion of an interaction term i + i t.
To model the variation in absenteeism among workers receiving ART by initial CD4 count, we use a generalisation of the Cox model which accounts for intraindividual correlation in absence hazard rates due to unobserved heterogeneity. These "shared frailty models" are preferred as other methods commonly used to analyse sickness absences underestimate true effect sizes and have lower statistical power (Christensen, Andersen, Smith-Hansen, Nielsen, and Kristensen, 2007) . 1 In this model, the hazard rate for the jth absence of individual i is given as
where i is the individual-level log frailties. Our controls include age, sex, marital status, tenure, job grade, diagnosis of TB, and the year employment commenced. We also include indicators for the year ART was initiated in the analysis to capture secular improvements in the toxicity, efficacy, and the ease of dosing of treatment (Lee, Amin, & Carr, 2014; Laskey & Siliciano, 2014) , as well as time-varying macroeconomic conditions. We have included additional dummies for the two outlying sites to reflect any systematic differences in doctors' advice and preferences, although doctors at these sites would have been subject to the same company-wide guidance and practices. ART initiation and subsequent treatment would not generally have been subject to idiosyncratic doctor's preferences within treatment site, as all those enrolled in the HIV wellness programme were reviewed at quarterly appointments, where the worker was seen by any available medical officer on duty. To capture the disutility of travelling to treatment, we have constructed a variable capturing the round trip journey time from the mine to the treatment site based on travel time computed from Google Maps. This variable has been used to construct additional dummies for sites close to the treatment site (<30 min round trip travel time), and sites far from the treatment site (30-90 min and >90 min). We also include absenteeism in the month preceding ART initiation as an independent variable to capture unobserved factors affecting selection into treatment. For example, less motivated workers might be expected to have more absences and delay treatment. However, this variable may also control out variation in health, associated with delaying treatment that we would like to capture. Estimates including this variable should therefore be regarded as overly conservative.
RESULTS
The effect of the rising thresholds for ART therapy can be seen clearly in Figure 1 , where the distribution of CD4 counts at ART initiation, have shifted to the right over time. In 2009, some of those treated lie above the prevailing WHO threshold of 200 cells/ l while in 2016, by which time WHO advocated universal eligibility, large proportions of HIV positive employees were still commencing treatment at relatively low CD4 counts. Figure 2 shows how CD4 counts recover following ART initiation. On average, those who initiate ART at a count less than 200 cells/ l take 4 years to reach an immune system strength reflective of the lowest 3% of counts in a sub-Saharan 
Employment separation
In the years following ART initiation, 170 out of the 775 workers on ART in our data set separated from the firm. Our data is therefore right censored for the remainder, where date of eventual separation is not known.
It is not clear a priori that survival in the workforce for those initiating ART at low CD4 counts should be lower than for those initiating at higher counts because sicker workers will have less alternative employment options. We examine how the initial CD4 count affects employment separation by plotting survival rates for workers on ART (Figure 3) . We estimate that, four years after commencing ART, 77% of workers with an initial CD4 count of less than 200 will remain in the workforce. Survival rates are higher for the other two categories at all time periods following ART initiation, and Notes. All workers on ART at some point between Jan2009 and Mar2017. Origin is date initiated ART. The models also include controls for year of employment commenced (<1990, 1990-1999, 2000-2004, 2005-2009, 2010-2017) , year ART initiated (<2010, 2010-2012, 2013-2014, 2015-2017) , marital status, treatment site, and round trip travel time to treatment site (<30 mins, 30-90 mins, and ≥90 mins).
Baseline absences are absences in month preceding treatment. * p < 0.05, ** p < 0.01.
after 4 years the estimated survival rates are 82% and 83% for CD4 250-349 and CD4 ≥ 350 respectively. Although the data is noisy, there are some visual evidence to suggest that survival rates diverge over time.
The differences between the three groups are seen to be more pronounced when we adjust for possible confounders using the Cox proportional hazards model of time to separation in Table 2 . We see that starting ART at CD4 200-349 leads to a 22% lower risk of separation relative to starting ART at the reference level CD4 < 200, although this is not statistically significant (hazards ratio [HR] = 0.778, p = 0.153). The risk of separation is even lower when ART is initiated at CD4 ≥ 350 at 37% below the risk of separation for the CD4 < 200 category (HR = 0.628, p = 0.039). In the second set of estimates, we control for endogenous selection into disease stage at ART initiation by including baseline absenteeism. Results are seen to be largely unchanged. Venkataramani et al. (2014) find that differences in labour outcomes by CD4 count disappear within 1 year, implying the effect of initial CD4 count on risk of separation varies over time, thus violating the proportional hazards assumption. We therefore test for evidence that the initial CD4 coefficients are time-varying. The initial CD4 count is interacted with time in the third set of estimates, but these coefficients are seen to be statistically insignificant (CD4 200-349: HR = 1.028, p = 0.766 and CD4 ≥ 350: HR = 1.016, p = 0.897) and the null hypothesis for the exclusion of these two interaction terms is accepted by a likelihood ratio test, 2 (2) = 0.09, p = 0.686. Also, a plot of scaled Schoenfeld residuals with survival time shows no correlation for each of the initial CD4 categories, confirming that the proportional hazards assumption is satisfied ( Figure A1 in Appendix) and formal statistical tests do not reject the null hypothesis that the slope is equal to 0 for each category (CD4 
Absenteeism
Following ART initiation, the 775 workers on ART in our data set had a total of 51,364 sickness absences. The mean number of sickness absences was 68 (1.6 per month), the median was 37 absences; 33 persons had no absences and one person had 785 absences over 97 months. Our sickness absence data is right censored as before.
In Figure 4 , we plot cumulative monthly absenteeism by CD4 count at ART initiation. Sickness absences accumulate rapidly in the first months after commencing ART especially for those with the lowest CD4 counts. The plots continue to diverge over time, giving a cumulated difference of 44 days of sickness absence between those with an initial count of less than 200 cells/ l and those with an initial count of greater than or equal to 350 cells/ l after 4 years. Notes. All workers on ART at some point between Jan2009 and Mar2017. Origin is date initiated antiretroviral therapy (ART) in first two sets of estimates. In the third set, the origin is two years before ART initiation and the data is right censored at ART initiation. The models also include controls for year employment commenced (<1990, 1990-1999, 2000-2004, 2005-2009, 2010-2017) , year ART initiated (<2010, 2010-2012, 2013-2014, 2015-2017) , marital status, treatment site, round trip travel time to treatment (<30 mins, 30-90 mins, ≥90 mins). Baseline absences are absences in month preceding treatment.* p < 0.05, ** p < 0.01.
These relationships are reflected in estimates from the Cox model with shared frailty. Table 3 demonstrates a strong graded relationship between initial CD4 count and sickness absence. Those initiating ART at CD4 200-349 had a 14% lower risk of absence, relative to starting ART at the reference level of CD4 < 200 (HR = 0.856, p = 0.000); while the risk for those initiating ART at CD4 ≥ 350 was lower again at 20%, relative to the reference level (HR = 0.796, p = 0.000). Adding baseline absences to capture endogenous selection results but initiating ART early is still clearly associated with lower absenteeism (HR = 0.903, p = 0.001 for CD4 200-349 and HR = 0.882, p = 0.001 for CD4 ≥ 350). As explained earlier, we regard estimates including this variable as being overly conservative. We then interact the initial CD4 count with time on ART. The CD4 < 200 interaction term is statistically insignificant, while the hazard ratio for the CD4 ≥ 350 interaction term is statistically different to 1 (HR = 0.9999, p = 0.000). This would imply that the differences in the risk of absence by initial CD4 count do not dissipate over time and actually increase marginally for CD4 ≥ 350. As a test of the robustness of these findings, time on ART was also entered in the model in a number of nonlinear forms to capture the spike in absences around ART initiation observed in Habyarimana et al. (2010) , that is, e −t and an indicator function t>1 , where t is time since ART initiation (in years). Results are similar (Table A2 ) and we therefore conclude that there is no evidence to suggest that the differences in risk of absence by initial CD4 count are lower in the long run. Other specifications where we allow effect sizes to vary over time and examine the number of absences post-ART (Table A3 ) confirm our conclusions.
It is clear from Figure 2 that HIV-infected workers initiating ART at CD4 <200 are at an advanced stage of immunosuppression for some time before treatment. Therefore, the hazard rate of absenteeism would be expected to be lower in the pre-ART period for those initiating at higher CD4 counts relative to those initiating at CD4 <200. This is indeed what we find in the final set of estimates in Table 3 where we consider only those absences occurring in the 2 years pre-ART. The effect sizes are slightly smaller than in the post-ART period, with those initiating ART at CD4 200-349 at an 8% lower risk of absence (HR = 0.908, p = 0.011) and those initiating ART at CD4 > 350 also at a 8% lower risk of absence (HR = 0.885, p = 0.002).
DISCUSSION
The aim of this study was to determine whether the timing of ART is associated with labour outcomes among workers in South Africa's largest coal mining company. From an employer perspective, both absenteeism and separation have clear negative economic effects. From the employee's perspective, workers may separate on improved terms, although in our sample of mostly unskilled workers and high blue-collar unemployment in South Africa this seems unlikely. We would therefore argue that these labour outcomes are negative for the employee also. Our analysis produced several original findings.
We find that employment separation and absenteeism differ between those initiating ART earlier in the disease course, when CD4 counts are still high, and those initiating later when their CD4 counts have already sunk to low levels. When ART was initiated at CD4 ≥ 350, the risk of separating from the company was 37% lower and the risk of absence was 20% lower than initiating at CD4 <200. Although studies to date have reported the positive effects of ART on productivity, labour force participation, and employment, very few have examined how labour outcomes vary by the timing of treatment initiation.
The most important previous study examining the association between disease stage at ART initiation and labour market outcomes is by Venkataramani et al. (2014) . Our study contributes substantially to the literature because we examine for the first time the association between disease stage and labour outcomes from the perspective of a private-sector company (whereas Venkataramani et al., 2014 look at this association from the perspective of patients enrolled in a public sector HIV treatment programme). We investigated the labour outcome absenteeism, which is much more responsive to health than either employment or wealth which are the outcomes reported in their study. Our data is further directly extracted from the mining company's human resources data rather than self-reported. Methodologically, the detailed event data that we have access to through this source-dates of absenteeism and employment separation-allow us to conduct survival analysis (rather than the binary choice approach taken in their work.). Overall, our study is similar in causal strength to their study, that is, both studies are nonexperimental rather than (quasi)experimental and use explicit co-variate control to reduce the threat of endogenous selection.
Our second finding is that these differences persist over time. Statistical tests indicated an absence of evidence to contradict the proportionality assumption, leading us to conclude that the risk of separating from the company and the risk of absence are lower for those initiating ART at higher thresholds for all times examined post-ART. Venkataramani et al, 2014 report labour force participation significantly differs between those initiating ART at CD4 ≥ 200 and those below this threshold, but that these differences quickly disappear. In our study, we similarly find no statistical difference in the risk of separation above and below this threshold, but find a large significant and persistent difference when contrasting those with initial CD4 ≥ 350 and those with initial CD4 < 200. Additionally, large significant and persistent differences in absences are observed above and below the 200 cells/ l threshold.
Many studies have reported that ART leads to full employment recovery and productivity levels comparable to uninfected workers (Razzano, Hamilton, & Perloff, 2006; Morineau et al., 2009; Habyarimana et al., 2010; Rosen et al., 2010; Bor et al., 2012) , but other studies record persistently lower employment despite recovery of work ability (Thirumurthy, Zivin, & Goldstein, 2008; Wagner, Ryan, Huynh, Kityo, & Mugyenyi, 2009; Booysen & Geldenhuys, 2016) . This may be due to nonadherence to the treatment regimen (Coetzee, Kagee, & Vermeulen, 2011) ; the effects of HIV-related stigma on social support and mental health (Tsai et al., 2011) or household disruption due to the disease (Wagner, Ryan, Huynh, Kityo, & Mugyenyi, 2011) . These factors are likely to be more severe in the later stages of disease when the HIV symptom burden is higher (Tsai et al., 2013) . The persistently worse labour outcomes that we observe in those treated at the lowest threshold may be due to these factors. Alternatively, continued immunosuppression after treatment and resultant debility would be expected to lead to worse labour outcomes, especially given the physically demanding nature of mining.
Our third original finding is that ART initiation at a higher CD4 count mitigates the decline in labour outcomes prior to treatment, observed when treatment begins at late disease stages. In a sample of a Kenyan tea estate workers, Larson et al. (2008) find that days worked started to decrease 9 months before treatment initiation. Bor et al. (2012) link clinical data with seven waves of longitudinal socio-economic data to demonstrate a deterioration in employment pre-ART and recovery post-ART, where the CD4 cell eligibility threshold for treatment was 200 cells/ l. Our contribution is to show how declines in labour outcomes vary by the level of immunosuppression at treatment start. We find that those initiating ART at CD4 ≥ 350 had an 8% lower risk of absence in the 2 years pre-ART than those initiating ART at CD4 < 200. Such differences have been suggested in prior studies (e.g., Thirumurthy et al., 2013) but have not been well-documented because both clinic-based longitudinal studies and community health interventions do not routinely capture socio-economic outcomes preinitiation.
At the start of the study period, the standard first-line ART regimen within the mining company consisted of two nucleoside reverse transcriptase inhibitors (zidovudine and lamivudine) in a fixed dose combination and one nonnucleoside reverse transcriptase inhibitor (efavirenz). When the improved fixed dose single pill combination of emtricitabine, tenofovir disoproxil fumarate, and efavirenz became available in South Africa in 2013, this soon became the standard treatment. These changes in drug regimens could have affected the labour effects of ART. It is somewhat less likely that these changes would have affected the labour effects of initiating ART at different HIV disease stages, which is what we are measuring here as the improved drug regimen should benefit people initiating ART in all disease stages. To ensure that the associations between disease stage at ART initiation and labour outcomes are not confounded by changing drug regimens and thus changing effectiveness, side effects, and toxicities over time, we control for calendar year in all of our main analyses. When we additionally interact calendar time with disease stage at ART initiation, we find no evidence of either significant or substantive heterogeneity of our observed associations.
Our findings indicating the positive effects of earlier treatment on labour outcomes suggest a sound economic rationale for increasing investments in HIV testing and interventions to accelerate treatment uptake among people living with HIV. Many firms and governments in sub-Saharan Africa have adopted universal test-and-treat policies, aiming to initiate people living with HIV as soon as possible following HIV infection. However, the majority of people living with HIV still initiates in late stages of disease when their CD4 counts have already fallen to relatively low levels-as we also show in this study. Approaches to remedy this situation require additional investment in HIV interventions. Examples of potential approaches include social marketing to promote HIV testing and treatment uptake (Wei et al., 2011) , HIV self-test kit distribution to allow people to test wherever and whenever they desire (Chanda et al., 2017; Ortblad et al., 2017) , and financial incentives or gifts to increase HIV testing and linkage to treatment programmes (McGovern et al., 2016) . The cost-benefit calculations for such supporting interventions should include the impact of earlier treatment on labour market outcomes, which are likely to at least partially offset costs.
Our findings may also have implications for social marketing content for HIV testing and treatment. One of the plausible reasons why men living with HIV are less likely to test and seek treatment than women living with HIV is that help-and care-seeking does not conform with ideas of male gender roles and conceptions of masculinity (Greig, Peacock, Jewkes, & Msimang, 2008; Choko et al., 2017) . It is plausible that social marketing messages emphasizing the effect of HIV treatment on continued employment and work performance can increase the appeal of HIV testing and treatment for men.
There is generally a paucity of research on the timing of ART initiation and labour outcomes. We have used a unique data set from a workplace health programme with detailed information on employment details, absences, and ART. Our study has several strengths. For one, the sample size of employees on ART used here is much larger than sample sizes available in previous studies leading to relatively precise effect size estimates. Moreover, using human resource records allow us to avoid social desirability and interviewer biases that often come with self-reported measures. Finally, our data has been recorded at daily intervals, which reduces errors resulting from data collection in larger intervals such as during annual survey visits.
Our study also has several limitations due to the nonexperimental design of our study and potential endogenous selection into disease stage at ART initiation. Pre-2015, workers receiving treatment at higher CD4 counts are more likely to have had stage 3 or 4 HIV infection with symptoms such as severe bacterial infection, wasting, pneumonia, and TB. Therefore, in our analysis, the categories of those initiating ART at higher CD4 counts would not reflect the CD4 < 200 category counterfactually treated before disease progression. As these categories will be sicker than in the counterfactual, any differences in labour outcomes between these workers and the CD4 < 200 category will be biased downwards. The effect sizes we report may then be underestimated. The group of those on ART at the lowest CD4 level will also include workers in later years who were eligible at the higher thresholds but lacked motivation to take-up treatment. Such individual characteristics may be correlated with future job attachment and hence labour outcome differences between these workers, and those who initiate at higher CD4 counts may be overestimated.
It is unlikely that the research question we are posing here will ever be answered with a randomized controlled trial, and the causal strength of this type of study will thus always be limited. Two quasi-experimental approaches have previously been used in the literature to answer similar research questions: regression discontinuity (Patenaude, Chimbindi, Pillay, and Bärnighausen, 2018) and individual fixed-effects analysis (Bor et al., 2012; Thirumurthy et al., 2013 , Zivin, Thirumurthy, & Goldstein, 2009 . Although these come with well-known limitations-regression discontinuity effect sizes are only causally strong in a small neighbourhood around the discontinuity, and the fact that individual fixed-effects analysis only allows inference among those who have changed their treatment status over the observation period. Neither approach is feasible given our data for this study and the precise research question that we are posing. Regression discontinuity is not possible because unlike in public sector HIV treatment programmes, CD4 count threshold rules for ART eligibility did not apply in the workplace health programme of the mining company whose data we are using here.
Instead, the programme advice was that ART should be initiated when a patient with HIV had full information and the physician judged that treatment was appropriate. Individual fixed-effects analysis is also not possible because our exposure of interest-disease stage at the time of ART initiation-is only determined once in a patient's life. Although our analysis is thus necessary, neither experimental nor quasi-experimental, it does have a few inferential strengths. First, the data is longitudinal, ruling out reverse causal effects. Second, to control for endogenous selection into disease stage at ART initiation, we include a number of variables in our survival analysis that are likely strong predictors of labour outcomes (sex, age, calendar time, job tenure, occupation, tuberculosis, access, worksite, and marital status). Importantly, we also add pre-ART values of one of our two outcome variables, absenteeism, to our regressions. In the regressions, with absenteeism as our outcome, these baseline values control for all past sources of endogenous selection into disease stage at ART initiation. In the regressions with employment separation as outcome variable, these baseline values capture those past sources for endogenous selection that are correlated with absenteeism. In the two regressions controlling for baseline absenteeism values, our results remain essentially the same, strengthening our belief that the observed conditional associations are indeed causal.
CONCLUSION
In sum, we use routine employment records linked to patient data from a workplace ART programme in South Africa's largest mining company to estimate the differences in the timing of treatment on employment separation and absenteeism. We find that employment separation and absenteeism differ between those initiating ART earlier in the disease course when CD4 counts are still high and those initiating later when their CD4 counts have already sunk to low levels. When ART was initiated at CD4 ≥ 350, the risk of separating from the company was 37% lower and the risk of absence was 20% lower than initiating at CD4 < 200. We cannot be sure that these effects are completely causal due to the nonexperimental design of our study and potential endogenous selection into disease stage at ART initiation, although our additional analyses suggest our findings are robust. Interpreted causally, our results would support the case for increased investment in early HIV testing and treatment. Table 2 ). (Probit) Model of 12-month out job termination probability. The models also include controls for year employment commenced (<1990, 1990-1999, 2000-2004, 2005-2009, 2010-2017) , year ART initiated (<2010, 2010-2012, 2013-2014, and 2015-2017) , marital status, treatment site, and round trip travel time to treatment (less than 30 min, 30-90 min, ≥90 min). * p < 0.05, ** p < 0.01. , 1990-1999, 2000-2004, 2005-2009, 2010-2017) , year ART initiated (<2010, 2010-2012, 2013-2014, 2015-2017) , marital status, treatment site, round trip travel time to treatment (<30 mins, 30-90 mins, ≥90 mins).* p < 0.05, ** p < 0.01.
